Evidence map›Paper›PMID 25131449›Full record

ReviewNeurobiology of disease2014

HDL and cognition in neurodegenerative disorders.

David A Hottman, Dustin Chernick, Shaowu Cheng, Zhe Wang, Ling Li

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurobiology of disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Metabolic Syndrome and Dementia Risk in Older Adults: A Narrative Review.The Kaohsiung journal of medical sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David A HottmanDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Dustin ChernickDepartment of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Shaowu ChengDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Zhe WangDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Ling LiDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA; Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: lil@umn.edu.
University of Minnesota · US

Funding

Protective Mechanisms of Statins in Alzheimer's DiseaseR01AG031846 · NIA · UNIVERSITY OF MINNESOTA · PI LI, LING · 2008 to 2012
$1.5M
NIA NIH HHS AG031846NIA NIH HHS R01 AG031846
6 · The paper itself

Abstract

High-density lipoproteins (HDLs) are a heterogeneous group of lipoproteins composed of various lipids and proteins. HDL is formed both in the systemic circulation and in the brain. In addition to being a crucial player in the reverse cholesterol transport pathway, HDL possesses a wide range of other functions including anti-oxidation, anti-inflammation, pro-endothelial function, anti-thrombosis, and modulation of immune function. It has been firmly established that high plasma levels of HDL protect against cardiovascular disease. Accumulating evidence indicates that the beneficial role of HDL extends to many other systems including the central nervous system. Cognition is a complex brain function that includes all aspects of perception, thought, and memory. Cognitive function often declines during aging and this decline manifests as cognitive impairment/dementia in age-related and progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A growing concern is that no effective therapy is currently available to prevent or treat these devastating diseases. Emerging evidence suggests that HDL may play a pivotal role in preserving cognitive function under normal and pathological conditions. This review attempts to summarize recent genetic, clinical and experimental evidence for the impact of HDL on cognition in aging and in neurodegenerative disorders as well as the potential of HDL-enhancing approaches to improve cognitive function.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsApolipoproteins EBrainCholesterol, HDLCognitionFemaleHumansHuntington DiseaseLipoproteins, HDLLiverLiver X ReceptorsMaleNeurodegenerative DiseasesOrphan Nuclear ReceptorsApolipoproteins ECholesterol, HDLLipoproteins, HDLLiver X ReceptorsOrphan Nuclear Receptors

Identifiers

PMID25131449
PMCPMC4252583
OpenAlexW2121135478

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.